Biogen's Hemophilia Business Spin-off Will Trade On Its Own Starting Thursday

By Emma Court Markets MarketWatch Pulse

Biogen Inc.'s hemophilia business will begin trading on its own as Bioverativ, with the ticker BIVV, starting Thursday. Biogen previously announced the spin-off in May of 2016, and said it would allow Biogen to focus on its neurological treatments. Biogen shares rose 0.8% in pre-market trade Wednesday. Company shares have sunk 1.9% over the last three months, compared with a 7.9% rise in the S&P 500 .

Continue Reading Below

Copyright © 2017 MarketWatch, Inc.